<code id='1C77B7BCBD'></code><style id='1C77B7BCBD'></style>
    • <acronym id='1C77B7BCBD'></acronym>
      <center id='1C77B7BCBD'><center id='1C77B7BCBD'><tfoot id='1C77B7BCBD'></tfoot></center><abbr id='1C77B7BCBD'><dir id='1C77B7BCBD'><tfoot id='1C77B7BCBD'></tfoot><noframes id='1C77B7BCBD'>

    • <optgroup id='1C77B7BCBD'><strike id='1C77B7BCBD'><sup id='1C77B7BCBD'></sup></strike><code id='1C77B7BCBD'></code></optgroup>
        1. <b id='1C77B7BCBD'><label id='1C77B7BCBD'><select id='1C77B7BCBD'><dt id='1C77B7BCBD'><span id='1C77B7BCBD'></span></dt></select></label></b><u id='1C77B7BCBD'></u>
          <i id='1C77B7BCBD'><strike id='1C77B7BCBD'><tt id='1C77B7BCBD'><pre id='1C77B7BCBD'></pre></tt></strike></i>

          Home / fashion / comprehensive

          comprehensive


          comprehensive

          author:explore    Page View:46587

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In